Clinical Trial Update: PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study [NA]

View source ↗

Summary

This clinical trial update describes a microdosing PET imaging study using a 124I-labeled cRGDY silica nanomolecular particle tracer in patients with melanoma a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Neoplasms
• Melanoma

Drugs mentioned

• I-124-labeled cRGDY silica nanomolecular particle tracer (Iodine-124-labeled cRGDY silica nanomolecular particle tracer)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Newly Diagnosed or Recurrent Metastatic Melanoma Patients, Malignant Brain Tumors | NA | Status: ACTIVE_NOT_RECRUITING